Report Overview:
Neuroendocrine tumors (NETs) are a type of cancer originating from cells that possess both endocrine (hormonal) and nervous system traits. These cells are found throughout the body, but NETs are most commonly observed in the gastrointestinal system, particularly the small intestine, where they are referred to as carcinoid tumors. Other areas where NETs may occur include the pancreas, lungs, and less frequently, other parts of the body.
NETs can either be benign or malignant, with the malignant forms being particularly dangerous due to their ability to spread to other parts of the body. Treatment options depend on the size, location, and stage of the tumor. These tumors can sometimes release hormones that cause a range of symptoms, known as carcinoid syndrome, which further complicates diagnosis and treatment.
Market Value:
As of 2024, the global market for neuroendocrine tumor treatment was valued at approximately USD 1495.40 million. Over the forecast period from 2024 to 2032, this market is projected to experience significant growth, with an expected compound annual growth rate (CAGR) of 5.90%. By 2032, the market size is anticipated to reach USD 2505.08 million, reflecting a growing demand for effective treatment solutions due to the rising prevalence of NETs globally.
By Types:
• Everolimus
• Sunitinib
• Lu-Dotatate
• Lanreotide
• Octreotide
By Applications: Hospitals
Key players include:
• Exelixis, Inc.
• Advanced Accelerator Applications
• Dauntless Pharmaceuticals, Inc.
• Hutchinson Medipharma Limited
• Ispen
• Novartis AG
• Including or Excluding key companies relevant to your analysis.
